JPRN-jRCT2071220025已完成3 期
A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older
Tanaka Yoshiyuki0 个研究点目标入组 63 人开始时间: 2022年7月8日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 63
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 50age old 至 ot applicable（—）
- 性别
- All
入选标准
- •The participant may have underlying chronic conditions if they are assessed to be stable as per the investigator's judgment.
- •- Is male or female, =>50 years of age, at the time of informed consent.
- •- Is pneumococcal vaccine-experienced, defined as prior receipt (=>1 year before enrollment)
排除标准
- •- has a history of invasive pneumococcal disease (IPD) within 3 years of Day 1
- •- has a known hypersensitivity to any vaccine components
- •- has impaired immunological function
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Vaccine-Experienced AdultsEUCTR2021-006679-41-ITMERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.700
进行中（未招募）
1 期
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Vaccine-Experienced AdultsPneumococcal diseaseMedDRA version: 20.0Level: LLTClassification code 10035644Term: Pneumococcal infection NOSSystem Organ Class: 100000004862EUCTR2021-006679-41-ESMerck Sharp & Dohme LLC700
进行中（未招募）
1 期
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Vaccine-Experienced AdultsEUCTR2021-006679-41-FRMerck Sharp & Dohme LLC717
已完成
3 期
A Phase 3 Clinical Trial to evaluate the safety and efficacy of treatment with 2 mg intralesional Allovectin-7® compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in subjects with recurrent metastatic melanomaNL-OMON31643Vical Incorporated15
进行中（未招募）
不适用
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma - Allovectin-7® Immunotherapy for Metastatic Melanoma (A.I.M.M)Recurrent metastatic melanomaMedDRA version: 9.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2007-004120-21-BEVical Incorporated375